Pentixapharm Announces Progress of Pivotal Phase 3 PANDA Study; Will Host Third Quarter Webcast on November 12, 2026

Pentixapharm’s Phase 3 PANDA study is cleared to start, with enrollment set for early 2027.

What the company is saying

Pentixapharm Holding AG is communicating that all major regulatory and ethical approvals for its pivotal Phase 3 PANDA study have been secured, including FDA Fast Track designation in July 2026 and central U.S. ethics committee approval. The company emphasizes that the study protocol, including primary endpoints and a planned enrollment of approximately 325 patients, received no objections from the FDA following its August 2026 submission. More than ten U.S. study sites, including leading academic medical centers and a specialized adrenal center, have been selected, and clinical investigators are in place. Agreements with these sites are still being negotiated, but the company maintains that first patient enrollment remains on track for the first quarter of 2027 and expects no material delays. Pentixapharm highlights independent external support for its approach, referencing studies from Europe, Asia, and Australia, but provides no detailed data. The announcement also previews a webcast on November 12, 2026, to discuss third quarter and nine-month 2026 results and further progress on the PANDA study.

What the data suggests

The announcement confirms that regulatory and ethical milestones for the Phase 3 PANDA study have been met, with FDA clearance to proceed and Fast Track status granted. The protocol for the study, covering approximately 325 patients, is finalized and approved by both the FDA and a central U.S. ethics committee, removing key barriers to initiation. More than ten U.S. study sites have been identified, and clinical investigators are ready, but site agreements are still under negotiation, meaning operational readiness is not yet complete. The company expects to begin enrolling patients in the first quarter of 2027, which is several months away. No financial data, such as cash position or funding for the study, is disclosed, and there is no evidence of site activation or patient enrollment to date. The announcement references external validation and a broad pipeline but does not provide supporting data, trial registration numbers, or technical details. The webcast scheduled for November 12, 2026, is positioned as the next source of financial and operational information.

Analysis

The announcement is upbeat, emphasizing regulatory progress and readiness for the pivotal Phase 3 PANDA study, including FDA Fast Track designation and ethics approval. However, most key claims are forward-looking: patient enrollment is not expected until Q1 2027, and agreements with study sites are still being negotiated. The study is capital intensive, involving over ten U.S. sites and 325 patients, but there is no disclosure of committed funding, cost, or financial impact. While the operational milestones are real, the benefits (clinical data, potential approval, commercialisation) are long-dated and uncertain. The language around pipeline breadth and external validation is promotional, with no supporting data or timelines. The absence of any financial figures or profitability metrics means the signal cannot be stronger than weak_positive.

Risk flags

• ●Operational execution risk remains, as agreements with participating study sites are still being negotiated and no sites are yet open for enrollment. Delays or difficulties in finalizing these agreements could push back the study start.
• ●The absence of disclosed financial figures, including available cash or committed funding for the 325-patient, multi-site Phase 3 study, raises questions about the company’s ability to sustain the trial through completion.
• ●The company’s assurance of no material timeline impact is unsupported by a detailed risk analysis or contingency plan, leaving open the possibility of unforeseen delays.
• ●While the company references independent external studies supporting its approach, it provides no data or citations, so the strength and applicability of this external validation cannot be independently assessed.
• ●The announcement references a broad pipeline and additional programs, but without technical details, timelines, or evidence of progress, these claims remain speculative and do not contribute to near-term value.

Bottom line

Pentixapharm has achieved key regulatory and ethical milestones for its pivotal Phase 3 PANDA study, clearing the way for a 325-patient trial at more than ten U.S. sites. Despite this progress, the operational groundwork is incomplete, as site agreements are still being negotiated and patient enrollment is not expected until early 2027. The company provides no financial disclosure regarding its ability to fund this capital-intensive study, and there is no evidence of site activation or patient recruitment. References to external validation and pipeline breadth are not substantiated with data or technical specifics. The webcast on November 12, 2026, will be the next opportunity to assess financial health and operational readiness. The most important takeaway is that while regulatory risk is now low, execution and funding risks remain high, and tangible value realization is still many months away.

Announcement summary

(FSE:PTP) Pentixapharm Holding AG announced completion of further key preparations for the pivotal Phase 3 PANDA study. The company will publish its third quarter and first nine months 2026 results on November 12, 2026. The PANDA study is designed to enroll approximately 325 patients. More than ten U.S. study sites have already been selected, including leading academic medical centers and a specialized adrenal center. Clinical investigators have been identified to conduct the study. Agreements with participating study sites are currently being negotiated to enable site openings for patient enrollment. The FDA confirmed in June 2026 that the PANDA study could proceed and granted Fast Track designation in July 2026. The FDA raised no concerns regarding the study protocol submitted in August 2026, which specifies the primary endpoints and the planned number of patients. The central U.S. ethics committee (Institutional Review Board) has approved the study protocol and consent documents. First patient enrollment is expected in the first quarter of 2027. The company does not expect any material impact on the further timeline of the study. A webcast to discuss third quarter and first nine months 2026 results and progress on PANDA will be held on November 12, 2026, at 3:00 p.m. CET. The PANDA study will evaluate [68 Ga]Ga-PentixaFor PET/CT for non-invasive subtyping in adults with confirmed primary aldosteronism. Independent studies from Europe, Asia, and Australia, most recently presented at EANM 2026, support the PANDA approach. Pentixapharm's pipeline is built on CXCR4 targeting and includes diagnostic and therapeutic programs in endocrine, cardiovascular, and oncological indications. The lead program, [68 Ga]Ga-PentixaFor, is being advanced into the registrational Phase 3 PANDA study. The PENTHERA program advances the CXCR4-directed theranostic platform into Phase I/II in oncology. Pentixapharm is also developing a next-generation antibody platform targeting CD24.

Disagree with this article?